SHASUNPHAR

Shasun Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held October 13, 2015 has allotted 31,600 equity shares of the face value of Rs.2 each under the ESOP Scheme.The paid up share capital of the Company has increased from Rs.13,44,47,704/ - consisting of 6,72,23,852 equity shares to Rs.13,45,10,904/- consisting of 6,72,55,452 equity shares.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 08, 2015 has approved the conversion of 71,00,000 convertible warrants into equity shares of the Company, which were issued on May 30, 2014 to M/s. Sequent Scientific Limited, Mumbai, on preferential basis at a price of Rs 110 per share including premium of Rs 108 per share.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 5, 2015 has approved the following: 1) Pro. Indira J Parikh, Independent Director, has resigned from the Board with effect from February 05, 2015. 2) Postal Ballot for obtaining approval of the public shareholders for the merger scheme. 3) Postal ballot for obtaining certain approvals of the shareholders.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors held on September 29, 2014 has approved a scheme of amalgamation between the Company and Strides Arcolab Limited wherein, wherein, the Company will amalgamate with Strides Arcolab Limited. The Scheme of amalgamation is subject to various statutory and regulatory approvals, as may be applicable.Further the Company has submitted a copy of the press release dated September 29, 2014, titled " Strides Arcolab and Shasun Pharmaceuticals combine to accelerate strategy and growth".

Shasun Pharmaceuticals Limited has informed the Exchange regarding outcome of board meeting held on May 30, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 21, 2014 has decided not to declare any interim dividend for the financial year 2013-14.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on April 23, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on December 12, 2013 decided to sell/ transfer the Company's unit situated at JN Pharma City, Vizag to a joint venture or any other person in any manner as the Board may consider appropriate subject to the approval of the shareholders. The Board has decided to obtain Shareholders approval by way of Postal Ballot.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 13, 2013, had reviewed the operations of the Company and had taken a decision to set up new joint venture company at Vizag to develop, manufacture and sell of veterinary products inclusive of both in API and Formulations in the global market with collaboration with SeQuent Scientific Ltd. Further, the Company has submitted a copy of Press Release dated July 13, 2013, titled "Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading A

Shasun Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held on March 29, 2012 allotted 65,78,947 equity shares to M/s. Caduceus Asia Mauritius Limited, Mauritius. The Company also appointed Dr. Sunny Sharma nominee of M/s. Caduceus Asia Mauritius Ltd as an Additional Director of the Company.

Shasun Pharmaceuticals Limited has informed the Exchange that pursuant to Shareholders' approval on July 29, 2011, the Company has concluded the sale of its Velachery property for a gross consideration of Rs.29 Crores.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on October 07, 2011 have considered the allotment of Convertible Warrants on Preferential basis to the Promoters & Directors of the Company.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 19, 2011 decided to issue and allot 15,00,000 warrants on preferential basis to promoters / promoter Group(s) and Directors with each warrant convertible into one equity share of the company as per the SEBI Guidelines and subject to the approval of the Share holders. The Board has decided to obtain Shareholders approval by way of Postal Ballot.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board, at its meeting held on June 27, 2009 has not recommended any dividend for current year due to losses.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that following points were recommended in the Board meeting held on May 26, 2005:- 1.The Board has approved to increase FII Limits to 30% in Equity Share Capital subject to approval from Shareholders and Regulatory Bodies. 2.The Board has recommended to subdivide the face value of the equity shares from Rs. 10 to Rs. 2 subject to approval from Shareholders and Regulatory Bodies.